<p>强生（NYSE:JNJ - 获取免费报告）周五交易中股价上涨了 0.9%。该股最高交易价为 151.46 美元，最后交易价为 150.93 美元。交易期间约有 2,046,255 股被交易，较平均每日交易量 7,919,047 股下降了 74%。该股此前收盘价为 149.61 美元。</p>
<p>获取 <strong>强生</strong> 的提醒：</p>
<h2>分析师评级变动</h2>
<ul>
<li>3 家行业巨头正在通过提高股息来回报投资者</li>
</ul>
<p>强生的股票曾受到多份分析师报告的关注。摩根士丹利将强生的目标股价从 164.00 美元上调至 169.00 美元，并在 4 月 16 日的报告中给予该公司 “持平” 评级。Stifel Nicolaus 将强生的目标股价从 170.00 美元下调至 155.00 美元，并在 1 月 23 日的报告中对该公司给予 “持有” 评级。桑福德·伯恩斯坦在 4 月 16 日的报告中重申了对强生股票的 “市场表现” 评级。Leerink Partners 将强生的评级从 “跑赢大盘” 下调至 “市场表现”，并在周二的报告中将该股的目标价从 169.00 美元下调至 153.00 美元。最后，富国银行将强生的目标价从 166.00 美元下调至 152.00 美元，并在 1 月 23 日的报告中给予该公司 “持平” 评级。共有 11 位股票研究分析师对该股给予 “持有” 评级，7 位给予 “买入” 评级，3 位给予 “强烈买入” 评级。根据 MarketBeat 的数据，强生目前的共识评级为 “适度买入”，共识目标价为 170.88 美元。</p>
<p><strong>阅读我们关于强生的最新研究报告</strong></p>
<h2>强生股票上涨 1.1%</h2>
<ul>
<li>3 只顶级大型制药股在美国投资超过 1000 亿美元</li>
</ul>
<p>该公司的 50 日移动平均线为 156.56 美元，200 日移动平均线为 154.00 美元。该公司的市值为 3640.5 亿美元，市盈率为 22.76，市盈增长比率为 2.56，贝塔值为 0.42。该公司的债务股本比率为 0.43，速动比率为 0.86，流动比率为 1.11。</p>
<p>强生（NYSE:JNJ - 获取免费报告）最近一次公布季度财报是在 4 月 15 日。该公司报告季度每股收益为 2.77 美元，超出市场共识预期的 2.59 美元，超出幅度为 0.18 美元。该公司季度收入为 218.9 亿美元，而市场共识预期为 216.5 亿美元。强生的股本回报率为 34.24%，净利润率为 18.20%。分析师预计强生在当前财政年度的每股收益将达到 10.58 美元。</p>
<h2>强生增加股息</h2>
<ul>
<li>强生的收益好于坏——现在是买入的时候吗？</li>
</ul>
<p>该公司最近宣布了季度股息，将于 6 月 10 日支付。5 月 27 日的股东将获得 1.30 美元的股息。该股息的除息日为 5 月 27 日。这比强生之前的季度股息 1.24 美元有所增加。这相当于年化股息 5.20 美元，收益率为 3.44%。强生的股息支付比率（DPR）为 57.84%。</p>
<h2>强生的内部交易</h2>
<p>在相关消息中，副总裁罗伯特·J·德克尔于 2 月 25 日出售了 6,999 股公司的股票，交易价格为 165.88 美元，总交易额为 1,160,994.12 美元。出售后，该副总裁现在直接持有 21,001 股公司股票，价值为 3,483,645.88 美元。这笔交易代表其持股减少了 25.00%。该交易已在证券交易委员会的法律文件中披露，相关文件可在此链接查看。此外，执行副总裁蒂莫西·施密德于 2 月 18 日出售了 403 股公司的股票，交易价格为 156.15 美元，总价值为 62,928.45 美元。出售完成后，该执行副总裁现在直接持有 15,098 股公司股票，价值约为 2,357,552.70 美元。这笔交易使其持股减少了 2.60%。该交易的披露信息可以在这里找到。公司内部人士目前持有该股的 0.16%。</p>
<h2>强生的机构交易</h2>
<p>机构投资者最近对该公司的持仓进行了调整。IFS Advisors LLC 在第四季度将其在强生股票中的持仓增加了 138.9%。IFS Advisors LLC 现在拥有 172 股公司股票，价值 25,000 美元，此前在上个季度增持了 100 股。WealthTrak Capital Management LLC 在第四季度购买了强生的新股份，价值约为 26,000 美元。Mountain Hill Investment Partners Corp.在第四季度购买了强生的新股份，价值约为 29,000 美元。Bay Harbor Wealth Management LLC 在第四季度购买了强生的新股份，价值约为 32,000 美元。最后，Conquis Financial LLC 在第四季度购买了强生的新股份，价值约为 33,000 美元。69.55% 的股票由机构投资者和对冲基金持有。</p>
<h2>强生公司简介</h2>
<p>（获取免费报告）</p>
<p>强生是一家控股公司，专注于医疗领域的产品研究、开发、生产和销售。它通过创新药物和医疗技术两个部门运营。创新药物部门专注于免疫学、传染病、神经科学、肿瘤学、心血管和代谢以及肺动脉高压。</p>
<h2>特色文章</h2>
<ul>
<li>我们更看好的五只股票超过强生</li>
<li>FAANG 股票是什么，它们是好的投资吗？</li>
<li>Meta 的 AI 增长五大关键支柱——扎克伯格的大胆愿景</li>
<li>你应该将这些沃伦·巴菲特的股票加入你的投资组合吗？</li>
<li>零售投资者正在大举押注火箭实验室——你也应该这样做吗？</li>
<li>多元化可以平滑收益并降低投资组合风险</li>
<li>通用电气航空：卡塔尔交易推动数十亿美元的增长引擎</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审查。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元于强生吗？</h2>
<p>在考虑强生之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而强生并不在名单上。</p>
<p>虽然强生目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

强生

<p>强生（NYSE: JNJ）股价上涨 0.9%，至 150.93 美元，交易量约为 200 万股。分析师意见不一，摩根士丹利将其目标价上调至 169 美元，而 Stifel Nicolaus 则下调至 155 美元。公司报告季度每股收益（EPS）为 2.77 美元，超出预期，并宣布每股股息增加至 1.30 美元。该股票市值为 3640.5 亿美元，市场共识评级为 “适度买入”</p>

<p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report)'s share price was up 0.9% during trading on Friday . The stock traded as high as $151.46 and last traded at $150.93. Approximately 2,046,255 shares were traded during trading, a decline of 74% from the average daily volume of 7,919,047 shares. The stock had previously closed at $149.61.</p>
<div class="lb-trans"><p>强生（NYSE:JNJ - 获取免费报告）周五交易中股价上涨了 0.9%。该股最高交易价为 151.46 美元，最后交易价为 150.93 美元。交易期间约有 2,046,255 股被交易，较平均每日交易量 7,919,047 股下降了 74%。该股此前收盘价为 149.61 美元。</p>
</div><p>Get <strong>Johnson &amp; Johnson</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>强生</strong> 的提醒：</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><ul>
<li>3 Industry Behemoths Are Rewarding Investors With Dividend Bumps</li>
</ul>
<div class="lb-trans"><ul>
<li>3 家行业巨头正在通过提高股息来回报投资者</li>
</ul>
</div><p>JNJ has been the subject of several analyst reports. Morgan Stanley raised their price target on Johnson &amp; Johnson from $164.00 to $169.00 and gave the company an &#34;equal weight&#34; rating in a report on Wednesday, April 16th. Stifel Nicolaus reduced their price objective on Johnson &amp; Johnson from $170.00 to $155.00 and set a &#34;hold&#34; rating for the company in a report on Thursday, January 23rd. Sanford C. Bernstein reiterated a &#34;market perform&#34; rating on shares of Johnson &amp; Johnson in a report on Wednesday, April 16th. Leerink Partners downgraded Johnson &amp; Johnson from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating and reduced their price objective for the stock from $169.00 to $153.00 in a report on Tuesday. Finally, Wells Fargo &amp; Company reduced their price objective on Johnson &amp; Johnson from $166.00 to $152.00 and set an &#34;equal weight&#34; rating for the company in a report on Thursday, January 23rd. Eleven equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, Johnson &amp; Johnson currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $170.88.</p>
<div class="lb-trans"><p>强生的股票曾受到多份分析师报告的关注。摩根士丹利将强生的目标股价从 164.00 美元上调至 169.00 美元，并在 4 月 16 日的报告中给予该公司 “持平” 评级。Stifel Nicolaus 将强生的目标股价从 170.00 美元下调至 155.00 美元，并在 1 月 23 日的报告中对该公司给予 “持有” 评级。桑福德·伯恩斯坦在 4 月 16 日的报告中重申了对强生股票的 “市场表现” 评级。Leerink Partners 将强生的评级从 “跑赢大盘” 下调至 “市场表现”，并在周二的报告中将该股的目标价从 169.00 美元下调至 153.00 美元。最后，富国银行将强生的目标价从 166.00 美元下调至 152.00 美元，并在 1 月 23 日的报告中给予该公司 “持平” 评级。共有 11 位股票研究分析师对该股给予 “持有” 评级，7 位给予 “买入” 评级，3 位给予 “强烈买入” 评级。根据 MarketBeat 的数据，强生目前的共识评级为 “适度买入”，共识目标价为 170.88 美元。</p>
</div><p><strong>Read Our Latest Research Report on Johnson &amp; Johnson</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于强生的最新研究报告</strong></p>
</div><h2>Johnson &amp; Johnson Stock Up 1.1%</h2>
<div class="lb-trans"><h2>强生股票上涨 1.1%</h2>
</div><ul>
<li>3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只顶级大型制药股在美国投资超过 1000 亿美元</li>
</ul>
</div><p>The company has a fifty day moving average of $156.56 and a two-hundred day moving average of $154.00. The company has a market cap of $364.05 billion, a PE ratio of 22.76, a price-to-earnings-growth ratio of 2.56 and a beta of 0.42. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11.</p>
<div class="lb-trans"><p>该公司的 50 日移动平均线为 156.56 美元，200 日移动平均线为 154.00 美元。该公司的市值为 3640.5 亿美元，市盈率为 22.76，市盈增长比率为 2.56，贝塔值为 0.42。该公司的债务股本比率为 0.43，速动比率为 0.86，流动比率为 1.11。</p>
</div><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.59 by $0.18. The company had revenue of $21.89 billion for the quarter, compared to the consensus estimate of $21.65 billion. Johnson &amp; Johnson had a return on equity of 34.24% and a net margin of 18.20%. As a group, analysts anticipate that Johnson &amp; Johnson will post 10.58 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>强生（NYSE:JNJ - 获取免费报告）最近一次公布季度财报是在 4 月 15 日。该公司报告季度每股收益为 2.77 美元，超出市场共识预期的 2.59 美元，超出幅度为 0.18 美元。该公司季度收入为 218.9 亿美元，而市场共识预期为 216.5 亿美元。强生的股本回报率为 34.24%，净利润率为 18.20%。分析师预计强生在当前财政年度的每股收益将达到 10.58 美元。</p>
</div><h2>Johnson &amp; Johnson Increases Dividend</h2>
<div class="lb-trans"><h2>强生增加股息</h2>
</div><ul>
<li>Johnson &amp; Johnson Earnings Were More Good Than Bad—Time to Buy?</li>
</ul>
<div class="lb-trans"><ul>
<li>强生的收益好于坏——现在是买入的时候吗？</li>
</ul>
</div><p>The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, May 27th. This is a boost from Johnson &amp; Johnson's previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a yield of 3.44%. Johnson &amp; Johnson's dividend payout ratio (DPR) is 57.84%.</p>
<div class="lb-trans"><p>该公司最近宣布了季度股息，将于 6 月 10 日支付。5 月 27 日的股东将获得 1.30 美元的股息。该股息的除息日为 5 月 27 日。这比强生之前的季度股息 1.24 美元有所增加。这相当于年化股息 5.20 美元，收益率为 3.44%。强生的股息支付比率（DPR）为 57.84%。</p>
</div><h2>Insider Buying and Selling at Johnson &amp; Johnson</h2>
<div class="lb-trans"><h2>强生的内部交易</h2>
</div><p>In related news, VP Robert J. Decker sold 6,999 shares of the firm's stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now directly owns 21,001 shares of the company's stock, valued at $3,483,645.88. This trade represents a 25.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at this hyperlink. Also, EVP Timothy Schmid sold 403 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now directly owns 15,098 shares in the company, valued at approximately $2,357,552.70. The trade was a 2.60% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在相关消息中，副总裁罗伯特·J·德克尔于 2 月 25 日出售了 6,999 股公司的股票，交易价格为 165.88 美元，总交易额为 1,160,994.12 美元。出售后，该副总裁现在直接持有 21,001 股公司股票，价值为 3,483,645.88 美元。这笔交易代表其持股减少了 25.00%。该交易已在证券交易委员会的法律文件中披露，相关文件可在此链接查看。此外，执行副总裁蒂莫西·施密德于 2 月 18 日出售了 403 股公司的股票，交易价格为 156.15 美元，总价值为 62,928.45 美元。出售完成后，该执行副总裁现在直接持有 15,098 股公司股票，价值约为 2,357,552.70 美元。这笔交易使其持股减少了 2.60%。该交易的披露信息可以在这里找到。公司内部人士目前持有该股的 0.16%。</p>
</div><h2>Institutional Trading of Johnson &amp; Johnson</h2>
<div class="lb-trans"><h2>强生的机构交易</h2>
</div><p>Institutional investors have recently made changes to their positions in the company. IFS Advisors LLC boosted its position in shares of Johnson &amp; Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company's stock worth $25,000 after acquiring an additional 100 shares in the last quarter. WealthTrak Capital Management LLC purchased a new stake in Johnson &amp; Johnson during the 4th quarter valued at approximately $26,000. Mountain Hill Investment Partners Corp. purchased a new stake in Johnson &amp; Johnson during the 4th quarter valued at approximately $29,000. Bay Harbor Wealth Management LLC purchased a new stake in Johnson &amp; Johnson during the 4th quarter valued at approximately $32,000. Finally, Conquis Financial LLC purchased a new stake in Johnson &amp; Johnson during the 4th quarter valued at approximately $33,000. 69.55% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>机构投资者最近对该公司的持仓进行了调整。IFS Advisors LLC 在第四季度将其在强生股票中的持仓增加了 138.9%。IFS Advisors LLC 现在拥有 172 股公司股票，价值 25,000 美元，此前在上个季度增持了 100 股。WealthTrak Capital Management LLC 在第四季度购买了强生的新股份，价值约为 26,000 美元。Mountain Hill Investment Partners Corp.在第四季度购买了强生的新股份，价值约为 29,000 美元。Bay Harbor Wealth Management LLC 在第四季度购买了强生的新股份，价值约为 32,000 美元。最后，Conquis Financial LLC 在第四季度购买了强生的新股份，价值约为 33,000 美元。69.55% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Johnson &amp; Johnson Company Profile</h2>
<div class="lb-trans"><h2>强生公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Johnson &amp; Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.</p>
<div class="lb-trans"><p>强生是一家控股公司，专注于医疗领域的产品研究、开发、生产和销售。它通过创新药物和医疗技术两个部门运营。创新药物部门专注于免疫学、传染病、神经科学、肿瘤学、心血管和代谢以及肺动脉高压。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than Johnson &amp; Johnson</li>
<li>What Are the FAANG Stocks and Are They Good Investments?</li>
<li>Meta's 5 Key Pillars for AI Growth—Zuckerberg's Bold Vision</li>
<li>Should You Add These Warren Buffett Stocks to Your Portfolio?</li>
<li>Retail Investors Are Betting Big on Rocket Lab—Should You Too?</li>
<li>Diversification Can Smooth Returns And Mitigate Portfolio Risk</li>
<li>GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过强生</li>
<li>FAANG 股票是什么，它们是好的投资吗？</li>
<li>Meta 的 AI 增长五大关键支柱——扎克伯格的大胆愿景</li>
<li>你应该将这些沃伦·巴菲特的股票加入你的投资组合吗？</li>
<li>零售投资者正在大举押注火箭实验室——你也应该这样做吗？</li>
<li>多元化可以平滑收益并降低投资组合风险</li>
<li>通用电气航空：卡塔尔交易推动数十亿美元的增长引擎</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审查。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Johnson &amp; Johnson Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元于强生吗？</h2>
</div><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑强生之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而强生并不在名单上。</p>
</div><p>While Johnson &amp; Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然强生目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

强生（NYSE:JNJ）股价上涨 0.9% - 以下是原因